Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data

/PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial...

Related Keywords

United States ,Amy Raskopf ,Evofem Bioscience ,Jack Hirschfield ,Saundra Pelletier ,Evofem Biosciences ,American College Of Obstetricians ,Securities Exchange ,Evofem Biosciences Inc ,Prnewswire Evofem Biosciences Inc ,Nasdaq ,Typical Use ,Chief Executive Officer ,Sexual Medicine ,American College ,Product Information ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Annual Report ,Used Alone ,Cochrane Database ,Systematic Reviews ,Nc ,